These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 31629805)

  • 21. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis.
    Peppers J; Paller AS; Maeda-Chubachi T; Wu S; Robbins K; Gallagher K; Kraus JE
    J Am Acad Dermatol; 2019 Jan; 80(1):89-98.e3. PubMed ID: 30554600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitis.
    Leung DYM; Paller AS; Zaenglein AL; Tom WL; Ong PY; Venturanza ME; Kuligowski ME; Li Q; Gong X; Lee MS
    Ann Allergy Asthma Immunol; 2023 Apr; 130(4):500-507.e3. PubMed ID: 36586583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis.
    Bissonnette R; Call RS; Raoof T; Zhu Z; Yeleswaram S; Gong X; Lee M
    Am J Clin Dermatol; 2022 May; 23(3):355-364. PubMed ID: 35368221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis.
    Fujita K; Yagi M; Moriwaki S; Yoshida M; Graham D
    J Dermatol; 2021 Nov; 48(11):1640-1651. PubMed ID: 34435694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
    Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
    JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
    Worm M; Thyssen JP; Schliemann S; Bauer A; Shi VY; Ehst B; Tillmann S; Korn S; Resen K; Agner T
    Br J Dermatol; 2022 Jul; 187(1):42-51. PubMed ID: 35084738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne.
    Mazzetti A; Moro L; Gerloni M; Cartwright M
    J Drugs Dermatol; 2019 Jun; 18(6):570. PubMed ID: 31251550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis.
    Eichenfield LF; Stein Gold LF; Lynde C; Guenther L; Greenberger S; Chu CY; Ghodsi Z; Vlahos B; Sanders P; Cha A; Canosa JM
    Dermatol Ther (Heidelb); 2024 Apr; 14(4):875-892. PubMed ID: 38546803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.
    Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Forman SB; Kuligowski ME; Kallender H; Sun K; Ren H; Simpson EL
    J Am Acad Dermatol; 2023 May; 88(5):1008-1016. PubMed ID: 36574595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
    Rosmarin D; Pandya AG; Lebwohl M; Grimes P; Hamzavi I; Gottlieb AB; Butler K; Kuo F; Sun K; Ji T; Howell MD; Harris JE
    Lancet; 2020 Jul; 396(10244):110-120. PubMed ID: 32653055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.
    Zhao Y; Zhang L; Ding Y; Tao X; Ji C; Dong X; Lu J; Wu L; Wang R; Lu Q; Goh AH; Liu R; Zhang Z; Zhang J
    Am J Clin Dermatol; 2021 Nov; 22(6):877-889. PubMed ID: 34374027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A starch, glycyrretinic, zinc oxide and bisabolol based cream in the treatment of chronic mild-to-moderate atopic dermatitis in children: a three-center, assessor blinded trial.
    Licari A; Ruffinazzi G; DE Filippo M; Castagnoli R; Marseglia A; Agostinis F; Puviani M; Milani M; Marseglia GL
    Minerva Pediatr; 2017 Dec; 69(6):470-475. PubMed ID: 29181960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
    Rosmarin D; Passeron T; Pandya AG; Grimes P; Harris JE; Desai SR; Lebwohl M; Ruer-Mulard M; Seneschal J; Wolkerstorfer A; Kornacki D; Sun K; Butler K; Ezzedine K;
    N Engl J Med; 2022 Oct; 387(16):1445-1455. PubMed ID: 36260792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
    Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
    Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
    Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
    Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-Pruritic Efficacy of Itch Relief Lotion and Cream in Patients With Atopic History: Comparison With Hydrocortisone Cream.
    Zirwas MJ; Barkovic S
    J Drugs Dermatol; 2017 Mar; 16(3):243-247. PubMed ID: 28301620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
    Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
    N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.
    Silverberg JI; Eichenfield LF; Hebert AA; Simpson EL; Stein Gold L; Bissonnette R; Papp KA; Browning J; Kwong P; Korman NJ; Brown PM; Rubenstein DS; Piscitelli SC; Somerville MC; Tallman AM; Kircik L
    J Am Acad Dermatol; 2024 Sep; 91(3):457-465. PubMed ID: 38777187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.
    Paller AS; Stein Gold L; Soung J; Tallman AM; Rubenstein DS; Gooderham M
    J Am Acad Dermatol; 2021 Mar; 84(3):632-638. PubMed ID: 32502588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
    Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
    Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.